Wepox 5000IU Injection contains Recombinant Human Erythropoietin Alfa, a glycoprotein hormone that stimulates erythropoiesis, the production of red blood cells, by acting on erythroid progenitor cells in the bone marrow. It is indicated for the treatment of anemia associated with chronic kidney disease (CKD), including patients on dialysis and those not on dialysis, as well as anemia due to chemotherapy in cancer patients. Wepox 5000IU is also utilized in managing anemia in patients undergoing elective surgery to reduce the need for allogeneic blood transfusions. The injection is administered subcutaneously or intravenously, with dosage individualized based on patient response and hemoglobin levels. Monitoring of hemoglobin concentration is essential to avoid excessive erythropoiesis, which may increase the risk of thromboembolic events. Common adverse effects include hypertension, headache, injection site reactions, and flu-like symptoms. Contraindications include uncontrolled hypertension, hypersensitivity to erythropoietin, and certain malignancies where tumor progression may be stimulated. Wepox 5000IU Injection should be used under strict medical supervision, with regular assessment of hematologic parameters and blood pressure to optimize therapeutic outcomes and minimize risks. Proper storage conditions must be maintained to preserve drug efficacy.